Patents by Inventor Louis E. Burton

Louis E. Burton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PAN-CELL SURFACE RECEPTOR-SPECIFIC THERAPEUTICS
    Publication number: 20100055093
    Abstract: Provided are pan-cell surface receptor-specific therapeutics, methods for preparing them and methods of treatment using them. Among the pan-cell surface receptor-specific therapeutics are pan-HER-specific therapeutics that interact with at least two different HER receptor ligands and/or dimerize with or interact with two or more HER cell surface receptors. By virtue of these properties, the therapeutics modulate the activity of at least two cell surface receptors and are useful for therapeutic purposes.
    Type: Application
    Filed: June 12, 2007
    Publication date: March 4, 2010
    Applicant: RECEPTOR BIOLOGIX INC.
    Inventors: H. Michael Shepard, Pei Jin, Louis E. Burton, Malgorzata Beryt
  • Isolation of neurotrophins from a mixture containing neurotrophin variants using hydrophobic interaction chromatography
    Patent number: 6953844
    Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: October 11, 2005
    Assignee: Genentech, Inc.
    Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck
  • Isolation of neurotrophins from a mixture containing other proteins and neurotrophin variants using hydrophobic interaction chromatography
    Patent number: 6812330
    Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: November 2, 2004
    Assignee: Genentech, Inc.
    Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck
  • Purification of NGF
    Publication number: 20040138431
    Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.
    Type: Application
    Filed: February 18, 2004
    Publication date: July 15, 2004
    Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck
  • Purification of NGF
    Publication number: 20020137893
    Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.
    Type: Application
    Filed: February 8, 2002
    Publication date: September 26, 2002
    Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck
  • Isolation of neurotrophins from a mixture containing other proteins and neurotrophin variants using hydrophobic interaction chromatography
    Patent number: 6423831
    Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: July 23, 2002
    Assignee: Genentech, Inc.
    Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck
  • Purification of NGF
    Patent number: 6184360
    Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: February 6, 2001
    Assignee: Genentech, Inc.
    Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck
  • Purification of recombinant human neurotrophins
    Patent number: 6005081
    Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.
    Type: Grant
    Filed: November 14, 1997
    Date of Patent: December 21, 1999
    Assignee: Genentech, Inc.
    Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck
  • Purified activin B composition
    Patent number: 5071834
    Abstract: A pharmaceutical composition and method are provided for erythropoietin therapy, such as treatment of an anemic disease, wherein an effective amount of activin with two beta.sub.B chains formulated in a pharmaceutically acceptable carrier is administered to a patient or animal in need of such therapy. Preferably the activin is human and the composition is administered parenterally.
    Type: Grant
    Filed: October 12, 1990
    Date of Patent: December 10, 1991
    Assignee: Genentech, Inc.
    Inventors: Louis E. Burton, Anthony J. Mason, Charles H. Schmelzer